OPKO Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on May 27, 2025. The report details a meeting of the Compensation Committee of the Board of Directors held on the same date to review and approve compensation matters for executive officers and non-executive employees.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
The primary material event reported is the grant of stock options and approval of cash bonuses to five named executive officers. The stock options have an exercise price of $1.31 per share, vest ratably over four years, and expire on the tenth anniversary of the grant date.
| Name | Title | Stock Options Granted | Bonus Payment |
|---|---|---|---|
| Phillip Frost, M.D. | Chief Executive Officer/Chairman | 500,000 | $480,000 |
| Jane H. Hsiao, Ph.D. | Vice Chairman/Chief Technical Officer | 500,000 | $450,000 |
| Elias A. Zerhouni, M.D. | Vice Chairman/President | 500,000 | $450,000 |
| Steven D. Rubin | Executive Vice President - Administration | 437,500 | $400,000 |
| Adam Logal | Senior Vice President/Chief Financial Officer | 437,500 | $475,000 |
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of risks and contingencies beyond the standard disclosure of the compensation event.
Key Facts for Investor Verification
- Option Terms: Verify the vesting schedule (ratably over four years) and expiration (10 years) for the 2,375,000 total options granted.
- Exercise Price: Confirm the $1.31 per share exercise price relative to the current market price of OPK common stock.
- Total Cash Outlay: Note the aggregate bonus payment of $2,255,000 approved for the named officers.
- Share Dilution: Assess the potential dilution impact of the new option grants on existing shareholders.